

State Agency Of Medicines

CERTIFICATE NUMBER: **JV-16/24/25 (API)**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with
Art. 111(5) of Directive 2001/83/EC as amended
Art. 94(1) of Regulation (EU) 2019/6 as amended

The competent authority of Estonia confirms the following:

The manufacturer: **PharmaSynth AS**

Site address: **Teaduspargi Tn 7, Tartu Linn, 50411, Estonia**

OMS Organisation Id. / OMS Location Id.: **ORG-100024746 / LOC-100054404**

Is an active substance manufacturer that has been inspected in accordance with Art. 123(6) of Regulation (EU) 2019/6 and Art. 111(1) of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2024-01-18**, it is considered that it complies with::

- The principles of GMP for active substances³ referred to in and Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (<http://eudragmdp.ema.europa.eu/>). This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/EC and Art. 80(5) of Directive 2001/82/EC is also applicable to importers.

² Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products
Veterinary Medicinal Products

Manufacture of active substance. Names of substances subject to inspection:

EMAPUNIL(en)

PRECURSORSFORRADIOACTIVEMEDICINALPRODUCTS(en)

NON-RADIOACTIVEREFERENCEMATERIALSFORRADIOACTIVEMEDICINALPRODUCTS(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES	
Active Substance:EMAPUNIL	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Chromatographic purification. Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps: Drying. Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance:PRECURSORSFORRADIOACTIVEMEDICINALPRODUCTS	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Chromatographic purification. Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps: Drying. Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Active Substance:NON-RADIOACTIVE REFERENCE MATERIALS FOR RADIOACTIVE MEDICINAL PRODUCTS	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Chromatographic purification. Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps: Drying. Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

2024-12-31

Name and signature of the authorised person of the
Competent Authority of Estonia

Confidential
State Agency Of Medicines
Tel: **Confidential**
Fax: **Confidential**